Breo Ellipta vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Breo Ellipta | US Nucala | |
|---|---|---|
| Generic name | fluticasone/vilanterol | mepolizumab |
| Drug class | ICS/LABA Inhaler | IL-5 Antagonist (Biologic) |
| Treats | Asthma, COPD | Severe eosinophilic asthma, COPD, nasal polyps |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | GSK |
| Year approved | 2013 | 2015 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | $75M |
| Common side effects | Oral thrush, Throat irritation, Headache, Common cold symptoms | Headache, Injection site reactions, Back pain, Fatigue |
Breo Ellipta
Frequently asked questions
Is Breo Ellipta or Nucala better?
Neither is universally "better." Breo Ellipta (fluticasone/vilanterol) and Nucala (mepolizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Breo Ellipta and Nucala?
Breo Ellipta is a ICS/LABA Inhaler made by GSK, while Nucala is a IL-5 Antagonist (Biologic) made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Breo Ellipta has the larger estimated TV advertising budget of the two.